Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Health

Metcela Raised $4 Million in Series B Funding to Launch a Phase I Clinical Trial for Heart Failure Therapy

Leave a comment



KANAGAWA, Japan (PRWEB)

Background and purpose of this round

Metcela Inc., established in 2016, is a clinical-stage biotechnology company focused on researching and developing potentially curative fibroblast-based therapies for chronic diseases with limited therapeutic options. The company’s mission is to provide these patients with an innovative and alternative treatment option.

Through basic research and various pre-clinical studies, Metcela has discovered that VCAM-1-positive cardiac fibroblasts (VCFs) were capable of stimulating proliferation of cardiomyocytes and improving cardiac function through formation of new lymphatic vessels, a process known as lymphangiogenesis.

Metcela’s first clinical pipeline is an autologous VCF therapy, which eliminates the needs for costly and debilitating immunosuppressive agents required for other allogeneic therapies, in order to achieve its maximal potential as a cell therapy. In addition, VCF product do not contain any types of stem cells nor require gene modification during its manufacturing; thus, there is essentially no concern regarding the risks for tumor formation or unexpected gene mutation.

With these innovative technological advantages, Metcela has been in a collaborative joint study with Japan Lifeline Co., Ltd. (JLL) and University of Tsukuba since 2018 to develop the cell therapy product MTC001, combining VCFs and a specialized catheter system for target delivery of the cells to the heart. Most recently, Metcela completed the construction of a cell processing facility in preparation for the launch of the first clinical trial of MTC001 in early 2021. The funds raised in this financing round will further strengthen the manufacturing and quality assurance of the products and accelerate the development of other pipelines.

About the newly appointed outside director, Kenji Yamada

Metcela also announces the appointment of a new outside director, Kenji Yamada. Mr.Yamada also serves as the director of Japan Lifeline Co., Ltd. and has worked in the business management sector for the past several years. Metcela and JLL are currently co-developing a new cell injection catheter, capable of delivering VCFs to precise targets in the heart. Mr.Yamada’s addition to the board will further solidify the relationship of the two companies and strategically position ourselves in the realm of cell therapy for heart failure, leading to accelerated development of MTC001.

About investors of this round

About Japan Lifeline Co., Ltd.

Japan Lifeline Co., Ltd. was founded in 1981 as a trading company specializing in medical devices in the cardiovascular field. Since then, the company has established its unique business model in which it has the trading company function that brings cutting-edge products from overseas manufacturers to Japan, and also the manufacturing function that develops and produces in-house products, reflecting needs of clinical practice. The company has business bases to cover all over Japan and close ties with physicians and medical institutions that are leading innovations in the cardiovascular field. Making use of such superior business resources, Japan Lifeline is pursuing initiatives to provide excellent medical devices to clinical settings.

URL: https://www.japanlifeline.com/

About Sony Innovation Fund

Sony Innovation Fund is dedicated to engaging with promising early-stage companies. Beyond investment, our mission is to provide access to the broader Sony world and its global network and collaborate with startups to foster business creation in new and existing areas of interest to Sony, catalyze a talented and passionate team, develop innovative and scalable technology, and explore new and emerging ecosystems.

URL: http://www.sonyinnovationfund.com/

About Tsukuba Exceed Fund (“TX Fund”)

TX Fund was created by Joyo Bank and The Joyo Industrial Research Institute, Ltd. in August of 2019. The focus of investment is in deep tech startups, particularly in seed rounds, founded by Japan’s leading research institutions, particularly around the Tsukuba Science City and the University of Tsukuba, and other surrounding areas along the Tsukuba Express line. TX Fund supports the startups by investing and provides hands-on support by utilizing the external expert network of Joyo Bank. Metcela was one of the first startups to be invested from TX Fund.

URL: http://www.jir-web.co.jp/business/fund/index.html

About Heart Failure

Heart failure is a complex condition in which the ability of the heart to pump blood decreases due to various causes. Majority of currently available treatment options only prevents the progress of the symptoms and preserve quality of life, and thus, is unable to cure the irreversible ailment.

About VCF

Metcela discovered VCAM-1-positive Cardiac Fibroblast (VCF), a specific type of fibroblast that re-establishes favorable microenvironment within the damaged heart tissues. VCF can easily be cultured and is known to induce lymphangiogenesis and enhance proliferation of cardiomyocytes to regenerate the damaged tissues of the heart. Metcela’s intellectual property is covered by several patents (JP6241893 and JP6618066).

Corporate Overview

Headquarter: Tsuruoka-shi, Yamagata

Research center: Life Innovation Center 3-25-22 Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-0821

Co-CEOs: Takahiro Iwamiya, Kenichi Nogami

Foundation: March 2016

Share article on social media or email:

health and fitness

Today Spivi® Announces Spivi Home, a New Service for Gyms and Fitness Studios That Offers in-Gym Cycling Experience for Home Users and in-Studio Users

Leave a comment


Spivi Home

Revital Alon, Certified Indoor Cycling Instructor

When you bring your facility to operate in the digital space, you open your business to many more potential members


LOS ANGELES (PRWEB)

Spivi®, an industry leader in digital interactive displays and performance tracking, announced Spivi Home, the world’s first service for fitness facilities, gyms and boutique studios to bring home users to ride together with gym members, virtually presented as avatars, in an immersive, animated scenery. Home users can connect using the Spivi Home app, which is launching on Windows and Mac computers and can connect with indoor cycling bikes equipped with ANT+ and BLE sensors. iOS and Android versions of the app will be available in Q3 2020.

Spivi technology collects both in-studio and at-home exercisers’ data such as power, cadence, speed, distance, and heart rate directly from the bikes and heart-rate sensors. During the class, home users see their live performance metrics on an app at home, and gym members see it on a display inside the studio. They both are able to take part in visual challenges and fitness tests. Home users can communicate with the instructor through gestures and a live video feed, and use their webcams to be seen by the instructor and others in the class, all in one application, without the use of a 3rd party streaming service.

Fitness facilities and studios can leverage the performance tracking features of Spivi to serve more users while complying with social distancing restrictions and also keeping them safe and engaged in an immersive workout experience. They can now seamlessly add home users to their daily classes.

Shay Amir, Spivi CEO, said: “When you bring your facility to operate in the digital space, you open your business to many more potential members. From a local business, it becomes a boundaryless facility, able to acquire more members from all over the nation. With a club-first approach, we help fitness facilities to grow their business, allowing them to use their Spivi systems to stream their indoor cycling classes to members, from the comfort of their home.”

Nir Hasson, Spivi CTO, said: “The new platform demonstrates how technology and great product design can lead to outstanding results. We are excited to bring our customers a cutting edge solution and help them in this competitive environment.”

Share article on social media or email:

Health

BCEN Launches New Emergency Nurse Career Preparedness Certificate

Leave a comment


News Image

Introducing the BCEN EDvantage Certificate Program.

“BCEN’s goal in developing this career preparedness certificate is to contribute to a stronger emergency nursing workforce right now and for the future,” said BCEN Executive Director Janie Schumaker.


OAK BROOK, Ill. (PRWEB)

The Board of Certification for Emergency Nursing (BCEN), the benchmark for board certification across the emergency nursing spectrum, has launched BCEN EDvantage, a new, first-of-its-kind emergency nursing certificate program designed to give final-year nursing students, recent grads and RNs aspiring to work in the emergency department (ED) a hiring and training advantage. Getting hired as an emergency nurse is typically highly competitive because of the challenging nature of the job as well as the high interest in the emergency specialty.

“BCEN’s goal in developing this career preparedness certificate is to contribute to a stronger emergency nursing workforce right now and for the future,” said BCEN Executive Director Janie Schumaker, MBA, BSN, RN, CEN, CENP, CPHQ, FABC. “Research, including the BCEN-initiated 2019 emergency nursing workforce study, makes it clear that immediate action is needed to ensure the U.S. healthcare system has an adequate pipeline of nurses who are as prepared as possible to step into the rigors and challenges of working in the ED — and the coronavirus pandemic has now raised those stakes even higher.”

“While BCEN EDvantage does not replace the training, mentoring and experience a new ED nurse will receive once hired, it does build foundational emergency nursing knowledge, gets nurses thinking about their role in an ED and how EDs function, and sets them up for the kind of lifelong learning that emergency nursing demands,” said BCEN’s Schumaker, who is a former ED director and chief nursing officer (CNO).

More specifically, BCEN EDvantage helps final-year nursing students, recent grads and RNs seeking to be hired in an ED acquire basic knowledge and skills related to core clinical, triage, and non-emergency and emergency incident preparedness by completing the following courses:

  • American Heart Association CPR course for healthcare providers,

  • Stop the Bleed,

  • ENA’s Emergency Severity Index Adult/Pediatric Course,

  • NIH Stroke Scale Training, and

  • FEMA’s Introduction to the Incident Command System and Introduction to the National Incident Management System courses.

The certificate program also helps aspiring ED nurses:

  • Develop ED-specific clinical and professional awareness.

  • Understand the roles emergency nurses and EDs play in communities.

  • Actively engage in their profession.

  • Explore the benefits of setting a career goal to be a board certified emergency nurse.

Backed by 40 years of experience offering rigorous, well-respected emergency nursing specialty certification programs, BCEN will confer a BCEN EDvantage digital badge, professional portfolio, and completion certificate to individuals who successfully meet the program requirements.

To be eligible to earn the BCEN EDvantage certificate, an individual must be within 12 months of graduating from an accredited nursing diploma, ADN or BSN program or be a recent graduate, and/or hold a current, unrestricted U.S. RN license or international equivalent. There is a $50 program fee and candidates must complete all requirements within 12 months of applying to the program. Complete details are available at https://bcen.org/EDvantage.

About BCEN

Throughout 2020, the independent, not-for-profit Board of Certification for Emergency Nursing (BCEN®) is celebrating 40 years of robust certification programs fostering empowered nurses across the emergency spectrum who contribute noticeably to patient care, safety and outcomes. Over 55,000 BCEN board certifications are currently held by registered nurses (RNs) who specialize in emergency, flight, critical care ground transport, pediatric emergency and trauma nursing. BCEN offers the Certified Emergency Nurse (CEN®), Certified Flight Registered Nurse (CFRN®), Certified Pediatric Emergency Nurse (CPEN®), Certified Transport Registered Nurse (CTRN®) and Trauma Certified Registered Nurse (TCRN®) certifications. The CEN, CFRN, CPEN, and TCRN certification programs are accredited by the Accreditation Board for Specialty Nursing Certification (ABSNC). Learn more at bcen.org. Follow BCEN on Facebook, LinkedIn and Instagram.

Share article on social media or email:

Health

Fertility Grants Up to $10,000 Made Possible by Shady Grove Fertility (SGF) and the Cade Foundation, Deadline July 1, 2020, for Fall Award

Leave a comment


July 1st is application deadline for fertility grants up to $10,000, made possible by Shady Grove Fertility (SGF) and the Cade Foundation.

The Tinina Q. Cade Foundation’s Family Building Grant is an annual award that provides up to $10,000 to needy, infertile families. The grant assists with the costs associated with infertility treatment or domestic adoption.


BALTIMORE (PRWEB)

With the grant application deadline on July 1, 2020, SGF, a longtime supporter of the Tinina Q. Cade Foundation, reminds interested applicants to apply for two grants that are available at this time: the general Cade Foundation Family Building Grant (available to anyone who has infertility), and the Dr. Stephen J. Greenhouse Grant (available only to SGF patients).

The Tinina Q. Cade Foundation’s Family Building Grant is an annual award that provides up to $10,000 to needy, infertile families. The grant assists with the costs associated with infertility treatment or domestic adoption. Family Building Grants can take the form of a cash award that is payable directly to the clinic or agency or a medication award that will be sent to the fertility center of the recipient. The grants are available for medical treatment of infertility and child adoption. The fertility medication grant is provided through a donation from EMD Serono.

The Dr. Stephen Greenhouse Grant, which covers one IVF cycle at SGF, is also available through the Tinina Q. Cade Foundation. The Dr. Stephen Greenhouse Grant is a grant specifically designated for an SGF patient to honor the memory and legacy of Dr. Greenhouse, an SGF physician and practice leader who died in an accident in July of 2018. Dr. Greenhouse was a well-respected leader and role model and known for his endless and tireless devotion to his life’s work—supporting his patients in overcoming infertility. Dr. Greenhouse was a strong supporter of the Tinina Q Cade Foundation and attended many Cade Foundation events with his family over the years.

To apply for these grants, please submit an application for the Cade Foundation Family Building Grant. SGF patients will automatically be considered for the Dr. Stephen Greenhouse Grant when they apply for a Family Building Grant.

To make a contribution in support of these grants, please visit the Cade Foundation.

To learn more about overcoming infertility, schedule a virtual physician consultation with an SGF physician by calling 1-888-761-1967 or visiting ShadyGroveFertility.com.

About Shady Grove Fertility (SGF)

SGF is a leading fertility and IVF center of excellence with more than 85,000 babies born and counting. With 38 locations throughout FL, GA, MD, NY, PA, VA, D.C., and Santiago, Chile, we offer patients virtual physician consults, individualized care, accept most insurance plans, and make treatment affordable through innovative financial options, including treatment guarantees. More physicians refer their patients to SGF than any other center. Call 1-888-761-1967 or visit ShadyGroveFertility.com.

The Tinina Q. Cade Foundation is a non-profit organization that is dedicated to serving the needs of families battling infertility through education, outreach, and grants that help couples pay for infertility treatment or domestic adoption. In the past decade, through events like the Race for the Family™, Corks with Cade™, and others, SGF and the Cade Foundation have raised more than $750,000 that is used to fund grants for fertility treatment and adoption for families with infertility and to build awareness about the 1 in 8 couples struggling with infertility. For more information about the Cade Foundation please visit http://www.cadefoundation.org.

Share article on social media or email:

Health

Compound Solutions Inc. and Axcess Global Sciences win in court against New U Life

Leave a comment


Our IP is strong and growing. The verdict in the New U Life case is vindication, as well as a clear message to all partners that we’ll defend our IP.


CARLSBAD, Calif. (PRWEB)

Axcess Global Sciences (AGS) owns BHB Patent No. 6,613,356. New U Life Corporation widely publicized its challenge to the BHB Patent and lost.

  • Certain Exogenous Beta-Hydroxybutyrate Nutraceutical Products, Docket No. 3400 (United States International Trade Commission, filed July 24, 2019).

  • New U Life Corporation v. ITC, Docket No. 2020-1214 (United States Court of Appeals for the Federal Circuit, filed Dec. 6, 2019).

The Federal Circuit Action has dismissed New U Life’s case with prejudice. “With prejudice” means the ruling is final, and New U Life has potential liability for the defendant’s attorney’s fees and financial damage.

Over the last two years, Compound Solutions (CSI) and Axcess Global Sciences (AGS), partners in patented goBHB®-branded beta-hydroxybutyrate, have vigorously defended goBHB®’s intellectual property from suppliers and marketers trying to capitalize on the growing ketogenic market.

Rob Rogers, one of the founders and managing partners of AGS said, “Our IP is strong and growing. The verdict in the New U Life case is vindication, as well as a clear message to all partners that we’ll defend our IP. We’re open for business, so please reach out to Compound Solutions to use our patented goBHB®.”

Past violators in question have marketed their ketone products in direct violation of Patent No. 6,613,356, which is exclusively licensed by CSI and sold as branded goBHB®. CSI and AGS worked with those violators and ultimately reached agreements that converted defendants into new customers.

Matt Titlow, CEO of CSI, said, “We’re proud to say we’re partners with those we’ve settled with. We’re here to say that our competitive pricing, goBHB® brand, patent and business-friendliness enable our partners to thrive.”

Compound Solutions’ goBHB is the world’s best-selling patented BHB. Compound Solutions has a long history of working with its partners to strongly defend intellectual property (IP). Customers trust CSI to defend IP and provide unique ingredients customers can successfully market to end-consumers.

Rogers added: “We now have 13 granted patents in the ketone space. We’re invested for the long term.”

Customers working with branded and patented goBHB® are assured the material is regulatorily-compliant, self-affirmed GRAS, Informed-Choice/Informed-Sport certified, and patent-protected. Furthermore, CSI’s goBHB manufacturer has registered the ingredient with local regulatory agencies, invested millions in tight pollution control, and successfully passed an FDA-audit. The factory is NSF-certified. These quality assurances are not found with generic BHBs.

About Compound Solutions, Inc.

Compound Solutions, Inc. is the go-to company representing and distributing unique, patented nutraceutical ingredients for the sports nutrition, functional food and beverage and nutritional supplement markets. Compound Solutions is the exclusive global supplier of goBHB®.

Share article on social media or email:

Health

ELITE & Global Accelerated Ventures (GAV) launch First FinTech/HealthTech Cohort in NYC

Leave a comment


Global Accelerated Ventures

“We are delighted to launch the ELITE GAV Cohort to support the growth of innovative fintech and healthtech businesses.” Tom Tyler, Global Head of Business Development


NEW YORK (PRWEB)

ELITE – London Stock Exchange Group’s (LSEG) international business support platform for private high-growth companies – and Global Accelerated Ventures (GAV) – a leading global innovation aggregator in Fintech and HealthTech – today announced the launch of the first ELITE GAV Cohort targeting Fintech and HealthTech companies in New York City.

The initiative will support high growth mid-market FinTech and HealthTech companies in New York through ELITE, providing access to resources, skills and networks to support candidate companies’ long-term growth.

ELITE GAV FinTech Lounge was launched today by Tom Tyler, Global Head of Business Development, ELITE, and Christopher Malter, Managing Partner, Global Accelerated Ventures, together with the support of sustaining partners worldwide.

Tom Tyler, Global Head of Business Development, ELITE: “We are delighted to launch the ELITE GAV Cohort to support the growth of innovative fintech and healthtech businesses. This collaboration with Global Accelerated Ventures leverages their strong network and expertise, building on the substantial success of ELITE Lounges in Europe.”

Designed to help businesses prepare and structure for their next stage of growth, ELITE provides training and mentoring to support management best practice and entrepreneurship. Today, more than 1,400 companies make up the growing international ELITE community. Companies come from across 45 countries, 35 sectors and are generating around €100 billion in combined revenues. Together they account for over 570,000 jobs across Europe and beyond.

“New York is the first market to launch an ELITE GAV Cohort, reflecting its importance to FinTech and HealthTech innovation globally,” said Malter. “The program has already begun accepting applications for its inaugural group of NYC companies. Go to http://www.gavfintech.com to register as we are still actively seeking applications.”

About Global Accelerated Ventures

Global Accelerated Ventures (GAV) is a globally recognized innovation aggregator partnering with industry leading corporations in the creation and management of Corporate Venture Studio Funds (CVSF). In this way, GAV minimizes risk and maximizes return and overall growth of its portfolio companies offering a clear path to success. For more information visit http://www.gaventures.co.

Media Contact:

Mark Macias

mmm@maciaspr.com

646-770-0541

Share article on social media or email:

Health

NeoTract Designates Dr. Manuel Eisenberg as UroLift® Center of Excellence

Leave a comment


News Image

“Dr. Manuel Eisenberg has earned the UroLift Center of Excellence designation for his dedication to improving the lives of men who previously suffered from BPH symptoms and delivering superior patient outcomes with the UroLift System treatment,” said Dave Amerson


PLEASANTON, Calif. (PRWEB)

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that Manuel Eisenberg, M.D., Ironwood Urology in Gilbert, AZ has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Eisenberg has achieved a high level of training and experience with the UroLift® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.

Recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines, the FDA-cleared Prostatic Urethral Lift procedure using the UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to BPH. The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.

The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.

“Dr. Manuel Eisenberg has earned the UroLift Center of Excellence designation for his dedication to improving the lives of men who previously suffered from BPH symptoms and delivering superior patient outcomes with the UroLift System treatment,” said Dave Amerson, president of the Teleflex Interventional Urology business unit.

Over 40 million men in the United States are affected by BPH, a condition that occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems and can cause loss of productivity, depression and decreased quality of life.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction, and retrograde ejaculation.

About the UroLift® System

The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function*1,2. Patients also experienced a significant improvement in quality of life. Over 100,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure using the UroLift System is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About NeoTract | Teleflex Interventional Urology

A wholly owned subsidiary of Teleflex Incorporated, the Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function*1,2. Learn more

at http://www.NeoTract.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit http://www.teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose

For Teleflex Incorporated: Jake Elguicze, 610.948.2836

Treasurer and Vice President, Investor Relations

Media:

Nicole Osmer, 650.454.0504

nicole@healthandcommerce.com

*No instances of new, sustained erectile or ejaculatory dysfunction 1. Roehrborn, J Urology 2013 LIFT Study

2.McVary, J Sex Med 2016

MAC00968-01 Rev A

Share article on social media or email:

Industry: Healthcare

MDstaffers Chief Operating Officer, Ryan Larkin, Named to Staffing…

Leave a comment


MDstaffers Chief Operating Officer, Ryan Larkin has been named in Staffing Industry Analysts' 40 Under 40 list. The list is a contemporary look at the industry's trailblazing leaders.

(PRWeb May 20, 2020)

Read the full story at https://www.prweb.com/releases/mdstaffers_chief_operating_officer_ryan_larkin_named_to_staffing_industry_analysts_40_under_40_list/prweb17132366.htm